Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / April 12, 2024 / RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, April 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
佛罗里达州奥兰多/ACCESSWIRE/2024年4月12日/RedChip Companies将在RedChip上播出对遗传技术有限公司（纳斯达克股票代码：GENE）和BioVie, Inc.（纳斯达克股票代码：BIVI）的采访 小股票，大资金 该节目是彭博电视台赞助的节目，将于美国东部时间4月13日星期六晚上7点（美国东部时间）。据估计，彭博电视在美国有7,300万个家庭可以观看。
Access the interviews in their entirety at:
访问访谈的全部内容，请访问：
Genetic Technologies:
遗传技术：
BioVie:
BioVie：
In an exclusive interview, Simon Morriss, CEO of Genetic Technologies, appears on the RedChip Small Stocks, Big Money Show on Bloomberg TV to provide a corporate update. Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering breast cancer, colorectal cancer, prostate cancer, ovarian cancer, coronary artery disease and Type-2 diabetes, a first-in-class test that can predict a person's risk in up to 70% of annual mortalities and morbidities before onset. The Multi-Risk test, along with integration of recently acquired DNA based products, underpin a broad and complementary portfolio of genomic based tests creating a significant competitive advantage. GENE's expanding product portfolio includes more than 50 risk assessment tests in 14 test categories covered by 25 patents granted and nine patents pending. In addition to its B2B model, GENE is also focused on expanding its direct-to-consumer testing programs. The global market for predictive genomics is expected to reach $4.6 billion by 2025, growing at a CAGR of 17%+.
基因技术首席执行官西蒙·莫里斯在接受独家采访时出现在RedChip上 小股票，大资金 在彭博电视上播出以提供公司最新情况。Genetic Technologies正在为其旗舰GeneType多风险测试执行B2B商业化战略，该测试涵盖乳腺癌、结直肠癌、前列腺癌、卵巢癌、冠状动脉疾病和2型糖尿病，这是一项同类首创的测试，可以在发病前预测一个人在高达70％的死亡率和发病率中的风险。多风险测试以及最近收购的基于DNA的产品的整合，为基因组测试的广泛而互补的产品组合奠定了基础，从而创造了显著的竞争优势。GENE不断扩大的产品组合包括14个测试类别的50多项风险评估测试，涵盖25项已授予的专利和9项正在申请的专利。除了其B2B模式外，GENE还专注于扩大其直接面向消费者的测试计划。到2025年，预测基因组学的全球市场预计将达到46亿美元，复合年增长率为17％以上。
Cuong Do, President and CEO of BioVie, appears on the RedChip Small Stocks, Big Money Show on Bloomberg TV to provide a corporate update. BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer's (AD) and Parkinson's (PD) and BIV201 for refractory ascites and HRS-AKI. BioVio recently reported data from a Phase 3 trial in AD that showed positive trending data showing that patients treated with NE3107 had treatment advantages compared to placebo on various cognitive, functional, and biomarker endpoints. The Company plans to launch Phase 3 trials in Alzheimer's, Parkinson's, and Ascites in 2024 and has multiple other efforts underway that may create additional catalysts.
BioVie总裁兼首席执行官Cuong Do出现在RedChip上 小股票，大资金 在彭博电视上播出以提供公司最新情况。BioVie是一家处于临床阶段的公司，正在开发其认为将是变革性的疗法，以克服神经变性和肝脏疾病中未得到满足的医疗需求。该公司正在开发用于阿尔茨海默氏症（AD）和帕金森氏症（PD）的 NE3107 以及用于难治性腹水和 HRS-AKI 的 BIV201。BioVio 最近报告了一项 AD 三期试验的数据，该数据显示了积极的趋势数据，表明与安慰剂相比，接受 NE3107 治疗的患者在各种认知、功能和生物标志物终点上具有治疗优势。该公司计划在2024年启动针对阿尔茨海默氏症、帕金森氏症和腹水的3期试验，并正在进行其他多项可能创造更多催化剂的努力。
About Genetic Technologies
关于基因技术
Genetic Technologies Limited (ASX:GTG)(Nasdaq:GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness, and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit .
基因技术有限公司（澳大利亚证券交易所股票代码：GTG）（纳斯达克股票代码：GENE）是一家多元化的分子诊断公司。通过其GeneType和EasyDNA品牌，成为健康、保健和严重疾病基因组学测试领域的全球领导者。GTG提供癌症预测测试和评估工具，帮助医生改善世界各地人们的健康状况。该公司拥有专有的风险分层平台，该平台是在过去十年中开发的，该平台整合了临床和遗传风险，为医生和个人提供可操作的结果。基因技术在肿瘤、心血管和代谢疾病的风险预测方面处于世界领先地位，继续开发风险评估产品。欲了解更多信息，请访问。
About BioVie
关于 BioVie
BioVie Inc. (Nasdaq: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer's and Parkinson's diseases. The Company conducted and reported efficacy data from its randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer's Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer's. A Phase 2 study of NE3107 in Parkinson's disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in "morning on" symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company's Orphan drug candidate BIV201 (continuous infusion terlipressin), with U.S. FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit
BioVie Inc.（纳斯达克股票代码：BIVI）是一家临床阶段的公司，开发用于治疗神经系统和神经退行性疾病以及晚期肝病的创新药物疗法。在神经退行性疾病中，该公司的候选药物 NE3107 可抑制导致神经炎症和胰岛素抵抗的 ERK 和 NFkB（例如肿瘤坏死因子信号）的炎症激活，但不抑制其稳态功能（例如胰岛素信号传导和神经元生长和存活）。两者都是阿尔茨海默氏症和帕金森氏病的驱动因素。该公司进行并报告了其随机、双盲、安慰剂对照、平行组、多中心研究的疗效数据，该研究旨在评估轻度至中度阿尔茨海默病（NCT04669028）患者的 NE3107。2022年12月的阿尔茨海默氏病临床试验（CTAD）年会上公布了一项由研究者发起的2期试验（NCT05227820）的结果，该试验显示接受NE3107治疗的患者的认知和生物标志物水平得到改善。估计有600万美国人患有阿尔茨海默氏症。NE3107 在帕金森氏病（NCT05083260）中的2期研究已经完成，2023年3月在瑞典哥德堡举行的阿尔茨海默氏症和帕金森氏病及相关神经系统疾病国际会议上公布的数据显示，与单独使用左旋多巴的患者相比，使用 NE3107 和左旋多巴联合治疗的患者的 “早起” 症状显著改善，运动控制具有临床意义的改善，没有与药物相关的不良事件。在肝脏疾病方面，正在评估和讨论该公司具有美国食品药品管理局快速通道地位的孤儿候选药物 BIV201（持续输注特利加压素），并获得美国食品药品管理局关于治疗慢性肝硬化引起的腹水的 BIV201 的三期临床试验的设计指导。该活性剂已在美国和约40个国家获准用于晚期肝硬化的相关并发症。欲了解更多信息，请访问
About RedChip Companies
关于红筹公司
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
RedChip Companies是一家5000公司，是一家国际投资者关系、媒体和研究公司，专注于微型股和小盘股公司。32年来，RedChip为其客户提供了具体、可衡量的业绩。我们的时事通讯， 小股票，大资金， 每周向60,000名投资者在线交付。RedChip为微型股和小盘股公司开发了业内最全面的服务平台。这些服务包括：股票研究的全球分销网络；美国主要城市的零售和机构路演；向股票经纪商、RIA、机构和家族办公室进行境外营销；产生数百万独特投资者观点的数字媒体投资者关系平台；投资者网络研讨会和群组电话；电视节目， 小股票，大资金，每周在美国彭博社播出；本地和全国市场的电视广告；企业和产品视频；网站设计；以及传统的投资者关系服务，包括新闻稿撰写、投资者演示文稿的编写、季度电话会议脚本撰写、战略咨询、筹集资金等。
To learn more about RedChip's products and services, please visit:
要了解有关RedChip产品和服务的更多信息，请访问：
"Discovering Tomorrow's Blue Chips Today"
“今天发现明天的蓝筹股”
Follow RedChip on LinkedIn:
在领英上关注 RedChip：
Follow RedChip on Facebook:
在脸书上关注 RedChip：
Follow RedChip on Instagram:
在 Instagram 上关注 RedChip
Follow RedChip on Twitter:
在推特上关注 RedChip：
Follow RedChip on YouTube:
在 YouTube 上关注 RedChip
Follow RedChip on Rumble:
在 Rumble 上关注 RedChip：
Subscribe to our Mailing List:
订阅我们的邮件列表：
Contact:
联系人：
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
戴夫·金特里
RedChip Companies
1-407-644-4256
info@redchip.com
SOURCE: RedChip
来源：RedChip